Hi-Tech Pharmacal Reports Higher Sales and Earnings for First Quarter.

AMITYVILLE, NY--(BUSINESS WIRE)--Sept. 15, 1997--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) reports sales and earnings for the first quarter ended July 31, 1997. Net sales were $4,708,000 compared to $4,155,000 for the same period last year, an increase of 13.3%. Net earnings were $145,000 ($.03 per share compared to a loss of $61,000 ($.01 per share) for the same period last year.

The Company attributed the higher sales and earnings to increased distribution of its product line, particularly through its Health Care Products Division. In commenting on the earnings, Bernard Seltzer, President and CEO, said, "While we continue to experience a sluggish environment for generic drugs, we are increasing our means of product distribution and continue to receive ANDA approvals from the FDA. Our Steri-Med Division continues to operate at a loss; however, we have a wonderful pipeline of products that will take full advantage of this state-of-the-art manufacturing facility. We remain optimistic about our business as we continue to focus our efforts and resources in areas we feel will have the best return for shareholders."

Hi-Tech Pharmacal Co., Inc. manufactures more than 100 prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid (creams, ointments, suppositories and gels) dosage forms, primarily for the private label market. The Company also manufactures sterile ophthalmic and otic products as well as providing sterile manufacturing contract services. The Company markets its own products under the name of H-T as well as Sooth-It brand, Diabetic Tussin, DiabetiDerm and DiabetiSweet brand product through its Health Care Products Division, and Steri-Optics through its Steri-Med Division.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, copies of which are available from the Company. -0-

                     HI-TECH PHARMACAL CO., INC.

                               Three months ended
                                    July 31,
                               1997         1996

Net Sales                  4,708,000       4,255,000
Income (loss) before
 taxes                       232,000        (101,000)
Provision for income
 taxes                        87,000         (40,000)
Net (loss) income            145,000         (61,000)
Net (loss) income per
 common share                   0.03           (0.01)
Weighted average number
 of shares outstanding     4,546,000       4,474,000

CONTACT: Hi-Tech Pharmacal Co., Inc.

David Seltzer, 516/789-8228